Actelion Sees 2012 Profit Unchanged on Prices, Competition

Actelion Ltd., the Swiss maker of the Tracleer lung treatment, aims for profit this year to be unchanged as the economic crisis puts pressure on drug prices and the company loses market share to Gilead Sciences Inc.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.